HEDD

Welcome to HEDD

The Human Epigenetic Drug Database (HEDD) is a comprehensive web-based database for epigenetic drugs, which focuses on the storage and integration of epigenetic drug datasets that were obtained from laboratory experiments that is essential for understanding the mechanism of action of these epigenetic drugs at a systematic level.

5-Aza-2'-deoxycytidine

Category:	DNMTi
Cas Number:	2353-33-5
Molecular Formula:	C₈H₁₂N₄O₄
Molecular Weight:	228.20528 g/mol
Smiles:	C1C(C(OC1N2C=NC(=NC2=O)N)CO)O
Description:	5-Aza-2'-deoxycytidine is a cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication.
synonyms:	Decitabine 5-Aza-2'-deoxycytidine 2353-33-5 2'-Deoxy-5-azacytidine 5-Azadeoxycytidine 5-aza-CdR 5-aza-dC AzadC Dacogen Dezocitidine Dacogen (TN) 5-Deoxy-2′-azacytidine 5-Aza-2′-Deoxycytidine MLS001332587 S1200_Selleck CHEBI:50131 5A2dc 5-aza-2-deoxycytidine 5-AZAdC NCGC_5ADOC Decitabine (USAN/INN) MolMap_000063 AC1L9PS9 SMR000857076 A3656_SIGMA MLS001332588 CHEMBL1201129 UNII-776B62CQ27 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one NSC127716 SBB066121 776B62CQ27 AC-1135 DB01262 TL8001944 FT-0082622 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one 4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one D03665 E-7373 NSC 127716 NSC-127716 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one DSSTox_CID_10432 DSSTox_RID_78849 DSSTox_GSID_30432 1,3, 5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy--D-erythro-pentofuranosyl)- Dacogen, 5-aza-2'-deoxycytidine,NSC 127716, Dacogen, DAC, Decitabine 4-amino-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one 2-Desoxy-5-azacytidine CAS-2353-33-5 Decitabine [USAN:INN:BAN] C8H12N4O4 Dacogenreg EINECS 219-089-4 4-amino-1-(2-deoxy-beta-d-erythro-pentofuranosyl)-s-triazin-2(1h)-on 2-deoxyazacytidine BRN 0617982 NCGC00166088-01 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,3,5-triazin-2-one 5-Aza-deoxycytidine CID451668 PubChem19115 SCHEMBL4006 cc-571 MLS006010136 CCRIS 8227 cid_451668 GTPL6805 s-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)- BDBM96274 CTK1A2018 SYN3036 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)- XAUDJQYHKZQPEU-KVQBGUIXSA-N HMS2235O03 ACT00147 HY-A0004 Tox21_112311 ABP001084 ANW-25144 CA-714 DAP000641 MFCD00043011 ZINC16929327 AKOS015895047 Tox21_112311_1 BCP9000593 CCG-208143 CS-0372 CS-O-01351 RL02744 Decitabine-Supplied by Selleck Chemicals NCGC00166088-02 NCGC00166088-05 BC677683 JNJ 30979754 JNJ-30979754 KB-41703 NU004639 BCP0726000271 AB0020011 DB-029060 FT-0603123 V0702 J10097 W-5049 AB00918337-07 J-700084 4-Amino-1-(2-deoxy-?-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one 105597-46-4 123795-43-7 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-o
Structure:
3D Conformer:	3D View
Downlaod:	Structure File Download (5.0KB)

Target list

Id	Drug Name	Target	PubmedId	Co-crystal Complex
1	5-Aza-2'-deoxycytidine	exonuclease V (RecBCD complex), alpha chain (Escherichia coli str. K-12 substr. MG1655)

Disease list

Conditions	Drug Name	Status	Nct Number	Phases
myelodysplastic syndromes MDS	5-Aza-2'-deoxycytidine	Completed		approved(N21790)
MDS	5-Aza-2'-deoxycytidine	Completed	NCT00796003	Phase 1
Leukemia MDS	5-Aza-2'-deoxycytidine	Completed	NCT00049582	Phase 1
Bladder cancer breast cancer melanoma	5-Aza-2'-deoxycytidine	Completed	NCT00030615	Phase 1
Esophageal lung cancer malignant mesothelioma	5-Aza-2'-deoxycytidine	Completed	NCT00019825	Phase 1
Leukemia	5-Aza-2'-deoxycytidine	Completed	NCT00042796	Phase 1
MDS leukemia lymphoma MM	5-Aza-2'-deoxycytidine	Completed	NCT00002980	Phase 1
Myeloproliferative disorders leukemia	5-Aza-2'-deoxycytidine Suberoylanilide hydroxamic acid	Completed	NCT00357708	Phase 1
Unspecified adult solid tumor	5-Aza-2'-deoxycytidine PEG-interferon alfa-2b	Completed	NCT00701298	Phase 1
Cancer	5-Aza-2'-deoxycytidine pegylated interferon-alfa 2b	Terminated	NCT00886457	Phase 1
Lymphoma	5-Aza-2'-deoxycytidine Valproic acid	Completed	NCT00109824	Phase 1
SCCjmesothelioma\|NSCLC	5-Aza-2'-deoxycytidine romidepsin	Completed	NCT00037817	Phase 1
LeukemiajMDS	5-Aza-2'-deoxycytidine Suberoylanilide hydroxamic acid	Completed	NCT00479232	Phase 1
Neuroblastoma childhood solid tumor	5-Aza-2'-deoxycytidine filgrastim pegfilgrastim cyclophosphamide doxorubicin hydrochloride	Completed	NCT00075634	Phase 1
Leukemia MDS	5-Aza-2'-deoxycytidine romidepsin	Completed	NCT00114257	Phase 1
Leukemia acute myelodysplastic syndromes	Suberoylanilide hydroxamic acid 5-Aza-2'-deoxycytidine	Completed	NCT00479232	Phase 1
Leukemia lymphoma MDS syndrome	Romidepsin 5-Aza-2'-deoxycytidine	Completed	NCT00114257	Phase 1
Small cell lung carcinoma	5-Aza-2'-deoxycytidine depsipeptide	Completed	NCT00037817	Phase 1
Lymphoma intestinal neoplasms	5-Aza-2'-deoxycytidine	Completed	NCT00089089	Phase 1
Leukemia	5-Aza-2'-deoxycytidine	Completed	NCT01378416	Phase 1

High-throughoutput Dataset

Title	Drug Name	Category	Sample type	PMID
Combinatorial treatment of DNMT inhibitor and LSD1 inhibitor results in cell growth inhibition and reexpression of epigenetically silenced genes (methylation)	5-Aza-2'-deoxycytidine clorgyline	DNMTi HDMi	human bladder cancer cell line (T-24); human leukemia cell line (HL60); human colon cancer cell line (HCT116)	24040395
Identification and functional analysis of epigenetically silenced microRNAs in colorectal cancer cells	5-Aza-2'-deoxycytidine	DNMTi	human colorectal cancer cells	21698188
Gene expression profiles of ovarian cancer cell lines in the presence and absence of a DNA methyltransferase inhibitor	5-Aza-2'-deoxycytidine	DNMTi	human epithelial ovarian cancer cell lines	21156726 18836486
Gene expression profiles of ovarian cancer cell lines in the presence and absence of a DNA methyltransferase inhibitor	5-Aza-2'-deoxycytidine epigallocatechin-3-gallate	DNMTi	human regulatory T cells	24476360
Real-time quantitative PCR analysis of Wnt signalling in human prostate cancer	5-Aza-2'-deoxycytidine	DNMTi	human prostate cancer cell
Gene expression profiling of oral cancer cell lines with or without AzC treatment	5-Aza-2'-deoxycytidine	DNMTi	humen oral cancer cell lines	23362108
Ras-induced epigenetic inactivation of RRAD promotes glucose uptake in a human ovarian cancer model [DGE-Seq]	5-Aza-2'-deoxycytidine	DNMTi	human ovarian cancer cells (T29 and T29H)	24648519
Genome-wide microRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers	5-Aza-2'-deoxycytidine trichostatin A	DNMTi HDACi	human non-small cell lung cancers cells (A549)	22282464
Expression profiling of DNMT1 inhibitors in HCT116 cells	5-Aza-2'-deoxycytidine	DNMTi	human HCT116 cells
Genome-wide DNA Methylation Analysis Reveals Novel Targets for Drug Development in Mantle Cell Lymphoma	5-aza-2'-deoxycytidine Suberoylanilide hydroxamic acid	DNMTi HDACi	human Mantle Cell Lymphoma (MCL) lines Mantle Cell Lymphoma (MCL) patients	20427703
Expression data identifying hypermethylated genes associated with acquired cisplatin resistance	5-Aza-2'-deoxycytidine	DNMTi	human Cisplatin-sensitive and -resistant SCC cells	20215521
DNA methylation of developmental genes in pediatric medulloblastomas identified by DAMD	5-Aza-2'-deoxycytidine	DNMTi	human medulloblastoma cell lines human colon Cancer Cell Line (HCT116)	19966297
Prostate_5azadC	5-Aza-2'-deoxycytidine	DNMTi	human prostate cancer cell lines （LNCaP，DU145，PC3，MDA-2A）	16166285
Identification of epigenetically silenced genes in tumor endothelial cells	Trichostatin A 5-Aza-2'-deoxycytidine	DNMTi HDACi	human tumor endothelial cells	17483324
Specific molecular signatures underlie response to decitabine in CMML [RNA-seq]	5-Aza-2'-deoxycytidine	DNMTi	mRNA profiling in bone marrow mononuclear cells (BM MNC) from 14 CMML patients;bone marrow mononuclear cells (BM MNC) from 39 CMML patients	25822018
Effects of DNA methyltransferase inhibitors (DNMTIs) on MDS-derived cell lines	5-Aza-2'-deoxycytidine	DNMTi	human MDS-derived cell lines
Effects of DZNep and 5-Aza-CdR on gene expression in MCF7 cells after 72 h treatment	5-Aza-2'-deoxycytidine	DNMTi	human breast adenocarcinoma cell lines	19509260
CCAAT/enhancer-binding protein alpha is epigenetically silenced by histone acetylation in endometriosis and promotes the pathogenesis of endometriosis: a novel therapeutic target	5-Aza-2'-deoxycytidine Valproic acid	DNMTi HDACi	human endometriotic cyst stromal cells (ECSCs)	23833041
A high-throughput screen of inactive X chromosome reactivation identifies the enhancement of DNA demethylation by 5-aza-2'-dC upon inhibition of ribonucleotide reductase-wide	5-Aza-2'-deoxycytidine Resveratrol	DNMTi HDACi	human myeloid leukemia cell lines	26468331
Identification of novel metastases-suppressor genes involved in breast cancer brain metastases (BCBM) formation	5-Aza-2'-deoxycytidine	DNMTi	human primary breast cancer cells (MDA-MB-231)	24833255

Complex list

PDBId

Drug Name

Target

method

PubmedId

About

The Human Epigenetic Drug Database (HEDD) is a comprehensive web-based database for epigenetic drugs, which focuses on integrating epigenetic drug studies based Omics data from high through experiments that is essential for understanding the mechanism of action of these epigenetic drugs at a systematic level.